Myeloid differentiation transcriptional machinery

The myeloid differentiation transcriptional machinery is a coordinated network of lineage-specific transcription factors and epigenetic regulators that orchestrate the maturation of hematopoietic progenitor cells into functional myeloid cells, such as neutrophils and monocytes (Sanz et al., 2019). Key components of this machinery include transcription factors like PU.1, C/EBPα, and RUNX1, which work in concert with epigenetic modifiers such as LSD1 (KDM1A), HDACs, and the Mediator complex to activate myeloid-specific gene programs (Maes et al., 2018; Cusan et al., 2018). In myeloid malignancies, particularly acute myeloid leukemia (AML), this machinery is frequently disrupted by genetic mutations or oncogenic fusion proteins (e.g., PML-RARA), resulting in a differentiation block where immature blasts proliferate without maturing (Sanz et al., 2019). Differentiation therapy aims to overcome this block by pharmacologically targeting specific nodes within the machinery to restore normal gene expression. For instance, ATRA and arsenic trioxide degrade the PML-RARA fusion protein, while LSD1 inhibitors and IDH inhibitors modulate the epigenetic landscape to reactivate pro-differentiation genes (DiNardo et al., 2018; Maes et al., 2018). While effective, these therapies can trigger differentiation syndrome, a systemic inflammatory response caused by the rapid maturation and activation of leukemic cells (Sanz et al., 2019).

Other names

Myeloid differentiation programMyeloid transcriptional networkMyeloid differentiation complexCore transcriptional machinery of myeloid differentiation

Reactivation of the myeloid differentiation program by inhibiting epigenetic repressors such as LSD1 and HDACs, or by degrading oncogenic fusion proteins like PML-RARA that cause differentiation arrest (Sanz et al., 2019; Maes et al., 2018).